Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 9:11:1451622.
doi: 10.3389/fsurg.2024.1451622. eCollection 2024.

Effectiveness of spinal cord stimulation in diabetic patients with chronic limb-threatening ischemia: small cohort study

Anna E Cyrek  1 , Dietrich Koch  1 , Arkadius Pacha  2 , Sonia Radunz  1
Affiliations

Effectiveness of spinal cord stimulation in diabetic patients with chronic limb-threatening ischemia: small cohort study

Anna E Cyrek et al. Front Surg. .

Abstract

Background: Chronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease (PAD). Patients with diabetes mellitus (DM) have a faster progression of PAD and a fourfold increased risk of CLTI compared to patients without DM. Epidural spinal cord stimulation (SCS) has been used as a method to improve microcirculation, relieve ischemic pain and reduce the number of amputations in patients with PAD. This is a retrospective small cohort analysis of patients with diabetes and the long-term treatment effect of spinal cord stimulation.

Methods: As the main outcome of the study, we evaluated the survival and amputation of 13 diabetic patients with chronic lower-limb ischemia who were not eligible for surgical or interventional therapy. Secondary outcomes included ankle-brachial index (ABI), ischemic pain intensity, quality of life, use of analgesic medications and skin wound outcomes analyzed during long-term follow-up.

Results: Between January 2010 and January 2017, 13 patients underwent SCS implantation in our vascular center. At 1-year follow-up, the limb salvage rate was 92.3% (12 of 13 patients), and limb ulcers healed in 75% of patients (6/8). No patient died during the one-year follow-up. A total of 4 of patients (31%) experienced major amputation during long-term follow-up, all of them were Fontaine stage IV. Pain intensity and quality of life improved significantly at 6-month follow-up (p < 0.05). ABI measurements were unaffected by SCS treatment. There were no complications related to the procedure or device.

Conclusions: SCS is a promising treatment option for diabetic patients unsuitable for endovascular or surgical revascularization. The method improves limb survival in diabetic patients with critical limb ischemia, provides significant pain control, and improves patients' quality of life. However, more studies are needed to clarify the indications for SCS and clarify its effects on the vascular system.

Keywords: critical limb-threatening ischemia; diabetic patients; limb salvage; long-term results; neuromodulation; peripheral arterial disease; quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Healing process of ulcers after admission.
Figure 2
Figure 2
Kaplan-Meier overall survival for all patients and according to Fontaine stage III and stage IV.
Figure 3
Figure 3
Kaplan-Meier amputation-free rate for all patients and according to Fontaine stage III and stage IV.
Figure 4
Figure 4
Intensity of ischemic pain assessed by using VAS before and after SCS implantation.
Figure 5
Figure 5
Skin temperature assessed by using VAS before and after SCS implantation.
Figure 6
Figure 6
Quality of life before and after SCS implantation.
Figure 7
Figure 7
Ankle-brachial-Index (ABI) before and after SCS implantation.
See this image and copyright information in PMC

References

    1. Teraa M, Conte MS, Moll FL, Verhaar MC. Critical limb ischemia: current trends and future directions. J Am Heart Assoc. (2016) 5(2):e002938. 10.1161/JAHA.115.002938 - DOI - PMC - PubMed
    1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group . Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. (2007) 45(Suppl S):S5–67. 10.1016/j.jvs.2006.12.037 - DOI - PubMed
    1. Feiring A. Footnotes on critical limb ischemia. JACC. (2008) 51(20):1975–6. 10.1016/j.jacc.2008.02.041 - DOI - PubMed
    1. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes–a review. Diabet Med. (2010) 27(1):4–14. 10.1111/j.1464-5491.2009.02866.x - DOI - PubMed
    1. TASC Steering Committee, Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II). Vasc Med. (2015) 20(5):465–78. 10.1177/1358863X15597877 - DOI - PubMed

LinkOut - more resources